Editorial: New innovations in therapeutic targets for gastrointestinal toxicity: exploring targets beyond the intestine

Andrea M Stringer^{1

2}

Affiliations

¹ Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia.
² Adelaide Medical School, The University of Adelaide, Adelaide, Australia.

Editorial

Andrea M Stringer. Curr Opin Support Palliat Care. 2020 Jun.

. 2020 Jun;14(2):118-119.

doi: 10.1097/SPC.0000000000000491.

Andrea M Stringer^{1

2}

¹ Health and Biomedical Innovation, School of Pharmacy and Medical Sciences, University of South Australia.
² Adelaide Medical School, The University of Adelaide, Adelaide, Australia.

No abstract available

References

1. Bowen J, Al-Dasooqi N, Bossi P, et al. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer 2019; 27:4023–4033.
1. Stringer AM, Al-Dasooqi N, Bowen JM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013; 21:1843–1852.
1. Feng Y, Huang Y, Wang Y, et al. Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PLoS One 2019; 14:e0218384.
1. Lehouritis P, Cummins J, Stanton M, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep 2015; 5:14554.
1. Parkar SG, Kalsbeek A, Cheeseman JF. Potential role for the gut microbiota in modulating host circadian rhythms and metabolic health. Microorganisms 2019; 7: pii: E41.